Cryosurgery in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES:

• Patients with localized renal cell carcinoma (T1a/T1b, ≤4 cm) who are poor surgical candidates or wish to preserve renal function

• Patients with low- to intermediate-risk prostate cancer (Gleason score ≤7, PSA ≤20 ng/mL, clinical stage ≤T2c) considering focal or whole-gland cryoablation as primary or salvage therapy after radiotherapy failure

• Patients with hepatocellular carcinoma (HCC) within Milan criteria, or colorectal liver metastases ≤3 cm, not amenable to surgical resection

• Patients with stage I non-small cell lung cancer (NSCLC) who are medically inoperable

• Patients with isolated bone metastases causing pain, or desmoid tumors of soft tissue

• Patients with pre-malignant skin lesions (actinic keratosis, CIN I–III, Bowen's disease, superficial BCC/SCC)

• Patients with locally recurrent prostate cancer after external beam radiotherapy, brachytherapy, or HIFU, evaluated for salvage cryoablation

• REQUIRED DIAGNOSTIC WORKUP:

• Contrast-enhanced CT (chest/abdomen/pelvis) or MRI for staging and lesion characterization

• PET-CT scan (FDG or PSMA-PET for prostate) to exclude metastatic disease before proceeding with local ablation

• Multiparametric MRI (mpMRI) of the prostate (PI-RADS scoring) for prostate candidates

• Renal function panel (eGFR, serum creatinine, BUN) for renal ablation candidates

• Liver function tests (Child-Pugh/MELD scoring), AFP, and hepatitis B/C serology for hepatic candidates

• Coagulation profile (PT/INR, aPTT, platelet count ≥80,000/µL required before percutaneous procedures)

• Echocardiography (ECHO) and cardiopulmonary assessment if general anaesthesia is planned

• Biopsy with histopathological confirmation (core needle biopsy under imaging guidance) — mandatory before ablation of visceral lesions

• Tumour markers as relevant (PSA, AFP, CEA, CA-125)

• CONTRAINDICATIONS:

• Uncorrectable coagulopathy or anticoagulation that cannot be safely bridged

• Active systemic infection or sepsis

• Tumors >5 cm in diameter (relative contraindication; may require staged or combination approach)

• Tumors immediately abutting major bile ducts (<1 cm) or central renal collecting system (risk of biliary stricture or urothelial injury)

• Patients with severely compromised renal function (eGFR <30 mL/min) where contrast imaging for guidance is required

• Platelet count <50,000/µL or INR >1.5 uncorrectable pre-procedure

• Cryoglobulinaemia, cold agglutinin disease, or Raynaud's phenomenon (systemic cold sensitivity disorders)

• Life expectancy <6 months due to metastatic burden where local ablation offers no survival benefit

PERCUTANEOUS IMAGE-GUIDED CRYOABLATION (MINIMALLY INVASIVE — GOLD STANDARD FOR SMALL SOLID TUMORS):

Under CT fluoroscopy, cone-beam CT, or MRI guidance, 1–5 cryoprobes (17-gauge or 2.4-mm diameter) are inserted through the skin directly into the target tumor under local anaesthesia with conscious sedation or general anaesthesia. The Galil Medical Iceforce™ or IceSense3™ system and the Endocare Cryocare™ CS system are the most widely deployed platforms. Argon gas flows through the probe tip causing the Joule-Thomson effect to generate temperatures of −40°C to −160°C, forming a monitored iceball that extends 1 cm beyond the tumor margin. Two to three freeze–thaw cycles are performed (typically 10-minute freeze / 8-minute passive thaw / 10-minute active thaw protocol). Real-time thermal monitoring with thermocouples placed at the tumor margin and adjacent critical structures ensures oncological adequacy while protecting collateral tissue. This approach is used for renal, hepatic, pulmonary, adrenal, and soft-tissue tumors. Hospital stay: outpatient to 23-hour observation.

LAPAROSCOPIC AND ROBOTIC-ASSISTED CRYOABLATION:

For renal tumors on the posterior or hilar aspect, or hepatic lesions not safely accessible percutaneously, laparoscopic (using a 4–5 port technique) or robotic-assisted (da Vinci Xi platform) cryoablation is performed under intraoperative laparoscopic ultrasonography (LUS). The robotic platform provides 10× magnification and 7-degree instrument articulation, allowing precise probe placement in anatomically constrained locations while simultaneously managing bleeding with bipolar coagulation. This approach is particularly favoured for hilar renal tumors where thermal ablation risks urothelial damage. Hospital stay: 1–3 days.

FOCAL AND WHOLE-GLAND PROSTATE CRYOABLATION:

Performed under transrectal ultrasound (TRUS) guidance with the patient in lithotomy position under spinal or general anaesthesia. Six to eight cryoprobes and 1–2 urethral warming catheters (UWC) are positioned transperineally using a brachytherapy grid template. The UWC circulates warm saline at 42°C to protect the urethra throughout freeze cycles. Periprostatic nerve-sparing is achieved by real-time temperature monitoring with thermocouples placed at the external sphincter, neurovascular bundles, and Denonvilliers' fascia. Focal cryoablation targets only the index lesion quadrant (guided by mpMRI-TRUS fusion biopsy mapping), preserving erectile and urinary function in the contralateral gland. The Galil Medical Visual-ICE system with MRI-real-time monitoring is available at premium centres. Hospital stay: 1–2 days; catheter removal at 1–2 weeks.

OPEN SURGICAL CRYOABLATION WITH INTRAOPERATIVE ULTRASOUND:

Reserved for large (>4 cm), multifocal, or complex tumors (e.g., multiple hepatic metastases) where percutaneous access is inadequate. An open laparotomy allows direct probe placement with IOUS guidance. Vascular inflow occlusion (Pringle manoeuvre) may be combined with hepatic cryoablation to extend iceball reach and reduce blood loss. This approach has largely been supplanted by laparoscopic methods but remains indicated in specific high-volume oncosurgical settings.

DERMATOLOGICAL AND GYNAECOLOGICAL CRYOTHERAPY:

Handheld open-spray or closed-probe liquid nitrogen systems (e.g., Brymill Cry-Ac®) deliver targeted freeze-thaw cycles (−196°C) to skin or cervical lesions. For CIN I–III, a single 3-minute freeze or double-freeze technique using a nitrous oxide or CO₂ cryoprobe shaped to the cervical os is standard. For actinic keratosis and superficial BCC, 5–30 second spray cycles with 1–3 mm lateral margins are applied. These are office-based procedures requiring no anaesthesia.

COMBINATION AND EMERGING APPROACHES:

• Cryo-immunotherapy: Percutaneous cryoablation combined with intratumoral or systemic anti-PD-1 agents (pembrolizumab, nivolumab) or CTLA-4 inhibitors (ipilimumab) to amplify the abscopal immune effect — available in clinical trial settings at select centres in India and the UAE.

• Cryo-TACE: Combination of transarterial chemoembolization (TACE) followed by cryoablation for HCC beyond ablation size limits.

• MRI-guided cryoablation (MR-guided focused cryoablation) for soft-tissue and bone tumors using real-time thermometry.

PHASE 1 — PRE-TRAVEL CONSULTATION (2–4 weeks before departure):

• Remote teleconsultation with the GAF Healthcare medical concierge team and the assigned specialist (interventional radiologist, urologist, or hepato-oncologist).

• Submission of imaging (DICOM files of CT/MRI/PET-CT), biopsy reports, blood work, and operative history for pre-procedure review.

• Fitness-to-travel assessment; cardiological clearance if ECHO or ECG indicates anaesthetic risk.

• Confirmation of procedure type (percutaneous vs. laparoscopic vs. focal prostate), estimated duration, and hospital.

PHASE 2 — ARRIVAL AND PRE-OPERATIVE WORKUP (Days 1–2):

• Airport pickup by GAF Healthcare's dedicated transport team.

• Hospital admission or outpatient registration; repeat bloodwork (CBC, CMP, coagulation panel, tumour markers) to confirm pre-procedure fitness.

• Anaesthesia pre-assessment and informed consent (procedure risks, alternatives, expected outcomes explained in detail).

• NPO (nil per os) from midnight before the procedure for visceral/prostate cases.

• For percutaneous cases under local anaesthesia and sedation: reduced fasting protocol (6 hours solids, 2 hours clear fluids).

PHASE 3 — THE PROCEDURE (Day 2 or 3):

• Patient transferred to interventional radiology suite, operating theatre, or robotic surgical suite.

• Anaesthesia administered (local + sedation, spinal, or general depending on approach).

• Real-time imaging guidance used to place cryoprobes with millimetre accuracy.

• Two to three freeze–thaw cycles completed; thermocouple readings documented throughout.

• Probes removed; haemostasis confirmed on immediate post-procedure imaging (CT or ultrasound).

• Total procedural time: 1–3 hours depending on number of lesions and anatomical complexity.

• Recovery room monitoring for 2–4 hours post-procedure.

PHASE 4 — HOSPITAL STAY AND IMMEDIATE RECOVERY (Days 3–5):

• Outpatient cryoablation (skin, cervix, small renal/hepatic lesions under local anaesthesia): discharge same day or next morning.

• Laparoscopic or robotic cryoablation: 1–3 days inpatient monitoring; pain managed with IV/oral analgesics (paracetamol, NSAIDs, low-dose opioids as needed).

• Post-ablation syndrome is common — mild fever (38–38.5°C), malaise, and fatigue for 3–7 days — managed symptomatically.

• Prostate cryoablation: urinary catheter remains in situ for 7–14 days; patient discharged on Day 2 with catheter and given outpatient catheter removal appointment.

• Foley catheter removal performed at outpatient visit; voiding trial assessed before discharge approval.

PHASE 5 — IN-COUNTRY RECOVERY (Days 5–21):

• Outpatient follow-up at Day 7 for wound check, catheter removal (if applicable), and repeat blood tests.

• Contrast-enhanced CT or MRI performed at Day 7–10 post-ablation to confirm iceball coverage and exclude early complications (haematoma, urinary leak, pneumothorax for lung cases).

• Activity restrictions: no heavy lifting (>5 kg) or strenuous exercise for 2–4 weeks; driving permitted after catheter removal and resolution of discomfort.

• Light walking encouraged from Day 1 post-procedure.

• Pain is typically well-controlled with oral analgesics by Day 5.

PHASE 6 — FIT-TO-FLY CLEARANCE AND DEPARTURE (Week 1–3):

• Percutaneous outpatient cryoablation (skin, cervical, small renal): fit to fly in 5–7 days.

• Laparoscopic/robotic visceral cryoablation: fit to fly in 10–14 days pending imaging confirmation of no complications.

• Prostate cryoablation: fit to fly after catheter removal, typically 10–14 days.

• Open surgical cryoablation: fit to fly in 2–3 weeks.

• GAF Healthcare physician issues a fit-to-fly certificate with medical summary for the patient's home oncologist.

PHASE 7 — LONG-TERM FOLLOW-UP (Remote/Home Country):

• 1-month, 3-month, and 6-month imaging follow-up (MRI or contrast CT) to assess treatment response using Modified RECIST or mRECIST criteria.

• PSA monitoring at 1, 3, 6, and 12 months post-prostate cryoablation (target: PSA nadir <0.5 ng/mL for primary; <0.1 ng/mL for salvage).

• Remote teleconsultation with the treating specialist via GAF Healthcare's digital platform for review of home-country imaging.

• Annual surveillance imaging and oncological review.